Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Pfizer's Paxlovid Becomes First Oral COVID-19 Therapy To Be Evaluated In Pediatric Clinical Study

Pfizer Inc (NYSE: PFE) has initiated a Phase 2/3 EPIC-PEDS trial to evaluate Paxlovid (nirmatrelvir and ritonavir tablets) in COVID-19 pediatric patients.

The trial will include non-hospitalized, symptomatic pediatric participants with a confirmed diagnosis of COVID-19 who are at risk of progression to severe disease. The Phase 2/3 trial has approximately 140 pediatric participants under 18 years of age.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.